secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2026-09-01T20:25:14+00:00
Accession:  0000875320-26-000264
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vertex names Jonathan Poole CFO effective Jan 1, 2027; Wagner stays COO
-----------------------------------------------------------------------

- Jonathan Poole, 51, appointed EVP & CFO effective Jan 1, 2027; was SVP Finance since March 2020.
- Charles Wagner ceases as CFO on that date but remains EVP & COO.
- Poole receives $750,000 base salary and 90% target bonus; severance equals 100% of base plus target bonus.
- Change-of-control agreement provides 100% base/target bonus, pro-rated bonus, and full equity vesting on qualifying termination.
- Poole previously CFO at Evelo Biosciences (2018-2020) and Genocea Biosciences (2014-2018).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/0000875320-26-000264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/vrtx-20260827.htm
  HTML page:      https://secwatch.observer/filing/0000875320-26-000264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer